Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
暂无分享,去创建一个
G. Tedeschi | A. Gallo | G. Donnarumma | M. Galdiero | A. Bisecco | R. Capuano | A. d’Ambrosio | N. Coppola | E. Grimaldi | M. Conte | A. d'Ambrosio
[1] N. Hahn. Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study , 2021, Neurology.
[2] K. Makar,et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.
[3] G. Cutter,et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis , 2021, JAMA neurology.
[4] E. Chu,et al. Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies , 2021, Clinical chemistry and laboratory medicine.
[5] A. Wallach,et al. The presence of SARS-CoV2 antibodies in MS patients , 2021, Multiple Sclerosis and Related Disorders.
[6] M. Sormani,et al. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.
[7] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[8] J. Thornton,et al. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab , 2020, Multiple Sclerosis and Related Disorders.
[9] A. Bar-Or,et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis , 2018, Neurology.
[10] Ashutosh Kumar Singh,et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis , 2015, Neurology.
[11] J. Kelton,et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. , 2013, Blood.